CAS 143664-11-3

Elacridar

Description:

Elacridar, with the CAS number 143664-11-3, is a chemical compound primarily recognized for its role as a potent inhibitor of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). It is classified as a small molecule and is often studied in the context of pharmacology and drug development, particularly for its potential to enhance the bioavailability of various therapeutic agents by preventing their efflux from cells. Elacridar is characterized by its ability to cross the blood-brain barrier, making it of interest in the treatment of central nervous system disorders. The compound exhibits a relatively high affinity for the target proteins, which can lead to increased intracellular concentrations of co-administered drugs. Its chemical structure includes multiple aromatic rings and nitrogen-containing functional groups, contributing to its lipophilicity and interaction with biological membranes. Elacridar is primarily utilized in research settings to investigate drug-drug interactions and to improve the efficacy of anticancer therapies by overcoming multidrug resistance.

Formula: C₃₄H₃₃N₃O₅

InChI: InChI=1S/C34H33N3O5/c1-40-28-9-5-7-26-32(28)36-31-25(33(26)38)6-4-8-27(31)34(39)35-24-12-10-21(11-13-24)14-16-37-17-15-22-18-29(41-2)30(42-3)19-23(22)20-37/h4-13,18-19H,14-17,20H2,1-3H3,(H,35,39)(H,36,38)

InChI key: InChIKey=OSFCMRGOZNQUSW-UHFFFAOYSA-N

SMILES: C(NC1=CC=C(CCN2CC=3C(CC2)=CC(OC)=C(OC)C3)C=C1)(=O)C4=C5C(C(=O)C=6C(N5)=C(OC)C=CC6)=CC=C4

Synonyms:

• 4-acridinecarboxamide, N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-
• Gf 120918
• Gf 129018
• Gg 918
• Gw 0918
• N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide
• N-{4-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl]phenyl}-5-methoxy-9-oxo-9,10-dihydroacridine-4-carboxamide
• Elacridar

Elacridar

CAS: 143664-11-3

Formula: C₃₄H₃₃N₃O₅

Purity: >98.0%(HPLC)

Color and Shape: White to Yellow to Green powder to crystal

Molecular weight: 563.65

Ref: 3B-E1371

Elacridar

CAS: 143664-11-3

Formula: C₃₄H₃₃N₃O₅

Purity: 98%

Color and Shape: Solid

Molecular weight: 563.6429

Ref: IN-DA00AOQ8

Elacridar

CAS: 143664-11-3

Formula: C₃₄H₃₃N₃O₅

Molecular weight: 563.65

Ref: 4Z-K-031035

Elacridar

CAS: 143664-11-3

Elacridar

Purity: ≥98%

Molecular weight: 563.64g/mol

Ref: 54-BUP15492

Elacridar

CAS: 143664-11-3

Formula: C₃₄H₃₃N₃O₅

Purity: ≥ 98.0%

Color and Shape: Off-white to yellow powder

Molecular weight: 563.64

Ref: 7W-GP5778

Elacridar

CAS: 143664-11-3

Elacridar (GG918) is a potent inhibitor of P-glycoprotein and BCRP.Cost-effective and quality-assured.

Formula: C₃₄H₃₃N₃O₅

Purity: 98.12% - >99.99%

Color and Shape: Solid

Molecular weight: 563.64

Ref: TM-T2657

Elacridar

CAS: 143664-11-3

Elacridar

Formula: C₃₄H₃₃N₃O₅

Purity: By hplc: 100% (Typical Value in Batch COA)

Color and Shape: solid

Molecular weight: 563.64g/mol

Ref: 54-BIE3025

Elacridar

Controlled Product

CAS: 143664-11-3

Applications A prototypical BCRP inhibitor. Inhibits the Bcrp1-mediated transport.
References Neville, K., et al.: Clin. Cancer Res., 10, 2525 (2004), Reardon, D., et al.: J. Clin. Oncol. 23, 9359 (2005), Pan, G., et al.: Drug Metab. Dispos., 35, 1165 (2007),

Formula: C₃₄H₃₃N₃O₅

Color and Shape: Neat

Molecular weight: 563.64

Ref: TR-E489000

Elacridar

CAS: 143664-11-3

Inhibitor of ABC transporters; oral bioenhancer for anti-cancer therapy

Formula: C₃₄H₃₃N₃O₅

Purity: Min. 98 Area-%

Color and Shape: Yellow Powder

Molecular weight: 563.64 g/mol

Ref: 3D-FE22653

Elacridar - Bio-X ™

CAS: 143664-11-3

Elacridar is an inhibitor of ATP-dependent transport, which is mediated by P-glycoprotein (P-gp). Functioning as an oral bioenhancer, Elacridar addresses multiple drug resistance in tumors, a common challenge in cancer treatment often linked to changes in the expression of protein inhibitors. Inhibition of P-gp by Elacridar is a key mechanism behind its effectiveness. P-glycoprotein, a well-characterized human ABC transporter of the MDR/TAP subfamily, acts as an ATP-dependent efflux pump with broad substrate specificity. Its increased expression in the intestines can hinder drug absorption, leading to reduced bioavailability and inadequate therapeutic plasma concentrations. Elacridar addresses this challenge by inhibiting P-gp, thereby increasing the bioavailability of coadministered drugs. Overall, Elacridar emerges as a promising option for the treatment of solid tumors, offering a strategic approach to overcoming multidrug resistance in cancer therapy.

Formula: C₃₄H₃₃N₃O₅

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 563.64 g/mol

Ref: 3D-BE300074